Abstract
Mycobacterium tuberculosis is the causative agent of tuberculosis, a lethal infection disease that attacks the lungs. Now it becomes the major global health risk because of very long latent period, the persistent increase of new cases, and the emergence of multidrug-resistant and extensively drug-resistant strains. Therefore, there is an urgent need for the development of new, safe and more efficient tuberculosis drugs. The shikimate pathway has been considered as the attractive drug target due to its essentiality in algae, higher plants, bacteria, and fungi, but absence from mammals. In this review, we focus on the recent development of a wide variety of inhibitors of type II Mycobacterium tuberculosis dehydroquinate dehydratase, the third enzyme of this pathway. The structural and mechanistic features of the enzyme for the design and discovery of the inhibitors have been described. The key factors on the structure, binding, and affinity of the inhibitors have been also highlighted. This may direct the further development of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors as potent tuberculosis drugs.
Keywords: Binding affinity, dehydroquinate dehydratase, drug design and discovery, inhibitor, Mycobacterium tuberculosis, tuberculosis.
Current Topics in Medicinal Chemistry
Title:Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors
Volume: 14 Issue: 1
Author(s): Yuan Yao and Li Ze-Sheng
Affiliation:
Keywords: Binding affinity, dehydroquinate dehydratase, drug design and discovery, inhibitor, Mycobacterium tuberculosis, tuberculosis.
Abstract: Mycobacterium tuberculosis is the causative agent of tuberculosis, a lethal infection disease that attacks the lungs. Now it becomes the major global health risk because of very long latent period, the persistent increase of new cases, and the emergence of multidrug-resistant and extensively drug-resistant strains. Therefore, there is an urgent need for the development of new, safe and more efficient tuberculosis drugs. The shikimate pathway has been considered as the attractive drug target due to its essentiality in algae, higher plants, bacteria, and fungi, but absence from mammals. In this review, we focus on the recent development of a wide variety of inhibitors of type II Mycobacterium tuberculosis dehydroquinate dehydratase, the third enzyme of this pathway. The structural and mechanistic features of the enzyme for the design and discovery of the inhibitors have been described. The key factors on the structure, binding, and affinity of the inhibitors have been also highlighted. This may direct the further development of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors as potent tuberculosis drugs.
Export Options
About this article
Cite this article as:
Yao Yuan and Ze-Sheng Li, Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors, Current Topics in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1568026613666131113150257
DOI https://dx.doi.org/10.2174/1568026613666131113150257 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review
Current Topics in Medicinal Chemistry Structure-Based Approaches to Drug Discovery Against Tuberculosis
Current Protein & Peptide Science Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Polymer Based Drug Delivery Systems for Mycobacterial Infections
Current Drug Delivery Bioactive Secondary Metabolites from Endophytic Fungi
Current Medicinal Chemistry Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill
Current Respiratory Medicine Reviews Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Utility of Non-Conventional Applications of Anti-VEGF Treatment in Selected Retinal Diseases
Current Drug Therapy Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Current Topics in Medicinal Chemistry Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Structure-Activity Relationships of Pyrrole Hydrazones as New Anti-Tuberculosis Agents
Medicinal Chemistry Synthesis and Antimycobacterial Activity of 3-(Arylaminomethyl)-5- (Pyridin-4-yl)-1,3,4-Oxadiazole-(3H)-thi-2-One Derivatives Against <i>Mycobacterium Tuberculosis</i> H37rv Strain
Current Bioactive Compounds